MX348902B - Métodos y composiciones adecuados para prevenir y tratar hiperleptinemia. - Google Patents

Métodos y composiciones adecuados para prevenir y tratar hiperleptinemia.

Info

Publication number
MX348902B
MX348902B MX2013012135A MX2013012135A MX348902B MX 348902 B MX348902 B MX 348902B MX 2013012135 A MX2013012135 A MX 2013012135A MX 2013012135 A MX2013012135 A MX 2013012135A MX 348902 B MX348902 B MX 348902B
Authority
MX
Mexico
Prior art keywords
preventing
treating
methods
compositions suitable
hyperleptinemia
Prior art date
Application number
MX2013012135A
Other languages
English (en)
Other versions
MX2013012135A (es
Inventor
Pan Yuanlong
Paul Middleton Rondo
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013012135A publication Critical patent/MX2013012135A/es
Publication of MX348902B publication Critical patent/MX348902B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

La presente invención se refiere a una composición que comprende ecuol o un precursor de ecuol para usarse en prevenir y tratar hiperleptinemia en un canino, en donde la composición es administrable al canino en una cantidad de 0.05 a 5 g/kg de peso corporal, y en donde la composición es administrable al canino en una cantidad suficiente para proporcionar una concentración de ecuol en suero sanguíneo de 200 µM.
MX2013012135A 2011-04-20 2012-04-17 Métodos y composiciones adecuados para prevenir y tratar hiperleptinemia. MX348902B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161517464P 2011-04-20 2011-04-20
PCT/US2012/033873 WO2012145281A2 (en) 2011-04-20 2012-04-17 Methods and compositions suitable for preventing and treating hyperleptinemia

Publications (2)

Publication Number Publication Date
MX2013012135A MX2013012135A (es) 2013-12-06
MX348902B true MX348902B (es) 2017-07-03

Family

ID=47042122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012135A MX348902B (es) 2011-04-20 2012-04-17 Métodos y composiciones adecuados para prevenir y tratar hiperleptinemia.

Country Status (11)

Country Link
US (1) US20140037583A1 (es)
EP (1) EP2699095A4 (es)
JP (1) JP2014515756A (es)
CN (1) CN103608011A (es)
AU (2) AU2012245639B2 (es)
BR (1) BR112013026896A8 (es)
CA (1) CA2833547A1 (es)
MX (1) MX348902B (es)
RU (1) RU2607109C2 (es)
WO (1) WO2012145281A2 (es)
ZA (1) ZA201308683B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900440A1 (en) * 2013-03-27 2014-10-02 Ge Healthcare As Kit for in situ provision of contrast media at user-defined concentrations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368784A1 (en) * 1999-04-20 2000-10-26 William J. Banz Methods of treating clinical diseases with isoflavones
WO2004039327A2 (en) * 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
WO2008020853A1 (en) * 2006-08-18 2008-02-21 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
EP1750523B1 (en) * 2004-03-17 2010-07-21 Nestec S.A. Compositions and methods for reducing or preventing obesity
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
US8226973B2 (en) * 2005-11-02 2012-07-24 Nestec, S. A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
US20090223990A1 (en) * 2008-02-04 2009-09-10 Bailey Kenneth S System for authenticating prescriptive drugs at the time of dispensing
WO2010019212A2 (en) * 2008-08-15 2010-02-18 Nestec S.A. Methods for enhancing energy metabolism

Also Published As

Publication number Publication date
US20140037583A1 (en) 2014-02-06
EP2699095A2 (en) 2014-02-26
RU2607109C2 (ru) 2017-01-10
ZA201308683B (en) 2015-05-27
BR112013026896A2 (pt) 2016-10-18
MX2013012135A (es) 2013-12-06
RU2013151423A (ru) 2015-05-27
AU2016203821A1 (en) 2016-06-30
BR112013026896A8 (pt) 2018-01-16
CA2833547A1 (en) 2012-10-26
JP2014515756A (ja) 2014-07-03
WO2012145281A3 (en) 2012-12-27
EP2699095A4 (en) 2015-04-15
CN103608011A (zh) 2014-02-26
WO2012145281A2 (en) 2012-10-26
AU2012245639B2 (en) 2016-06-30
AU2012245639A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2016016800A (es) Metodos para el tratamiento del sobrepeso o la obesidad.
MX2015008114A (es) Derivados de exendina-4.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX342257B (es) Derivados y análogos de oxaspiro [2.5] octano.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
IN2012DN02624A (es)
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
MX347570B (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos.
EP2898923A3 (en) Isoflavones for regulating sirtuin gene expression
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
WO2012078519A3 (en) 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2013012135A (es) Metodos y composiciones adecuadas para prevenir y tratar hiperleptinemia.
IN2014MN01407A (es)
WO2013188824A3 (en) Hexim-1 as a target of leptin signaling to regulate obesity and diabetes
WO2009108635A3 (en) Novel compositions for treatment of diseases related to activated lymphocytes
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
FG Grant or registration